FWM
FATE icon

Filbrandt Wealth Management’s Fate Therapeutics FATE Stock Holding History

Filbrandt Wealth Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-100
Closed -$2K – 402
2020
Q1 		$2K Buy
+100
New +$2.53K ﹤0.01% 178

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Filbrandt Wealth Management's FATE Position: Q2 2020 in Review

Filbrandt Wealth Management sold out of Fate Therapeutics (FATE) in Q2 2020, closing a stake of 100 shares — an estimated $2K sold.

Filbrandt Wealth Management first reported a position in FATE in Q1 2020 and held it in 1 quarter. The position peaked at $2K in Q1 2020. 202 funds tracked by Wall St. Rank hold FATE as of Q2 2020.

  • Filbrandt Wealth Management reported no remaining Fate Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Filbrandt Wealth Management sold 100 Fate Therapeutics shares in Q2 2020, an estimated $2K.
  • Filbrandt Wealth Management first reported a position in Fate Therapeutics in Q1 2020 and held it in 1 quarter.
  • Filbrandt Wealth Management's Fate Therapeutics position peaked at $2K in Q1 2020.
  • 202 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2020.

Based on Filbrandt Wealth Management's 13F filing for Q2 2020, filed 11 Aug 2020.